DIA 2017 Annual Meeting

Component Type: Session
Level: Intermediate
CE: ACPE 1.50 Knowledge UAN: 0286-0000-17-568-L04-P; CME 1.50; IACET 1.50; RN 1.50

As awareness and theory around patient engagement in the medical product life cycle have matured, stakeholders are now focusing on best practices and implementation of patient centric strategies. In this session, patient, industry, and regulatory stakeholders will share their perspectives on today’s meaning of effective engagement and what the future state of patient engagement will look like. Panelists will discuss what they believe should be the outcomes of their investments of effort and how we can engage patients to identify the outcomes that matter most. The idea of “return on engagement” will be explored: how do we measure what matters? How do we turn insights into regulatory utilities? And how do we capture the return – to drug and device development – on this investment in patient engagement?

Join Patient Engagement Community for a follow up Round Table discussion at 12:30pm in the Community Corner.

Learning Objectives

Describe the meaning of effective patient engagement and where it should take place during the medical product life cycle; Discuss approaches to involving patients in the determination of meaningful outcomes throughout the life cycle of medical therapies; Identify potential measures that could demonstrate the return on meaningful engagement for patient, regulatory, and industry stakeholders. Explore patient engagement in today’s policy environment and in the context of global harmonization.

Chair

Debra Lappin, JD

Speaker

Panelist
Anne C. Beal, MD, MPH

Panelist
Juan Garcia-Burgos, MD

Panelist
K. Kimberly McCleary

Panelist
Paul Kluetz, MD

Panelist
Ronald Joseph Bartek, MA